The stock of Silexion Therapeutics Corp (SLXN) has gone down by -14.48% for the week, with a -10.63% drop in the past month and a -56.30% drop in the past quarter. The volatility ratio for the week is 8.16%, and the volatility levels for the past 30 days are 11.02% for SLXN. The simple moving average for the past 20 days is -17.27% for SLXN’s stock, with a -96.05% simple moving average for the past 200 days.
Is It Worth Investing in Silexion Therapeutics Corp (NASDAQ: SLXN) Right Now?
The stock has a 36-month beta value of 0.05. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SLXN is 7.91M, and at present, short sellers hold a 5.36% of that float. On April 03, 2025, the average trading volume of SLXN was 14.06M shares.
SLXN) stock’s latest price update
Silexion Therapeutics Corp (NASDAQ: SLXN) has experienced a decline in its stock price by -4.62 compared to its previous closing price of 1.04. However, the company has seen a fall of -14.48% in its stock price over the last five trading days. globenewswire.com reported 2025-03-28 that Silexion’s new expanded dual-route strategy will integrate intratumoral and systemic administration to target both primary tumors and metastases, supported by strong preclinical data from SIL204 and previous promising clinical data from its first-generation product; Company shares its strategic roadmap for SIL204’s clinical development including plans to initiate human trials in H1 2026 Silexion’s new expanded dual-route strategy will integrate intratumoral and systemic administration to target both primary tumors and metastases, supported by strong preclinical data from SIL204 and previous promising clinical data from its first-generation product; Company shares its strategic roadmap for SIL204’s clinical development including plans to initiate human trials in H1 2026
SLXN Trading at -18.71% from the 50-Day Moving Average
After a stumble in the market that brought SLXN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.19% of loss for the given period.
Volatility was left at 11.02%, however, over the last 30 days, the volatility rate increased by 8.16%, as shares sank -31.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +28.57% upper at present.
During the last 5 trading sessions, SLXN fell by -14.66%, in comparison to the 20-day moving average, which settled at $1.1990. In addition, Silexion Therapeutics Corp saw -50.65% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for SLXN
The total capital return value is set at 19.05. Equity return is now at value -3.78, with -320.05 for asset returns.
Based on Silexion Therapeutics Corp (SLXN), the company’s capital structure generated 8.95 points at debt to capital in total, while cash flow to debt ratio is standing at -1.87. The debt to equity ratio resting at -1.13. The interest coverage ratio of the stock is -6285.5.
The liquidity ratio also appears to be rather interesting for investors as it stands at 0.64.
Conclusion
To sum up, Silexion Therapeutics Corp (SLXN) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
